Avirulent Live Bacterial Vaccines Cured of Plasmids Containing Antimicrobial Resistance Genes
Summary
USPTO published patent application US20260097106A1 for avirulent live bacterial vaccines cured of plasmids containing antimicrobial resistance genes. The application, filed September 19, 2023, covers a vaccine comprising live avirulent bacterial strains free of AMR gene-carrying plasmids, a synthetic curing plasmid, and methods for treating bacterial infections while preventing AMR gene transfer.
What changed
USPTO published patent application US20260097106A1 covering avirulent live bacterial vaccines cured of plasmids and transposons containing antimicrobial resistance genes. The application discloses a non-conjugative synthetic curing plasmid and methods for producing the cured bacterial strains. Claims include the vaccine composition itself, methods for treating or preventing bacterial infections, and methods for preventing AMR gene transference.
For pharmaceutical companies and vaccine developers, this patent application signals potential licensing opportunities for AMR-curing technology in live bacterial vaccines. Companies developing bacterial vaccines should conduct freedom-to-operate analyses to assess potential infringement risks. The technology addresses concerns about horizontal gene transfer of antimicrobial resistance in live vaccine platforms.
What to do next
- Monitor patent prosecution status
- Evaluate licensing opportunities
- Review freedom-to-operate implications
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AVIRULENT LIVE BACTERIAL VACCINES CURED OF PLASMIDS CONTAINING ANTIMICROBIAL RESISTANCE GENES
Application US20260097106A1 Kind: A1 Apr 09, 2026
Inventors
Hans Koehnk, Larry Koehnk
Abstract
A vaccine comprising a live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria, wherein the bacteria is cured of plasmids and/or transposons that contain AMR genes, and a non-conjugative synthetic curing plasmid that cures plasmids and/or transposons that contain AMR genes from such bacteria. A method for producing the live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria; a method for treating, preventing, or reducing the severity, duration, or incidence of clinical signs, of a virulent bacterial infection; and a method for preventing, or reducing the risk or incidence of transference of AMR genes are also disclosed.
CPC Classifications
A61K 39/0258 C12N 15/70 A61K 2039/522
Filing Date
2023-09-19
Application No.
19113283
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.